UniProtKB/Swiss-Prot Q02548: Variant p.Ile301Thr

Paired box protein Pax-5
Gene: PAX5
Feedback?

Variant information Variant position:

301 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Isoleucine (I) to Threonine (T) at position 301 (I301T, p.Ile301Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and hydrophobic (I) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs372989600 [ dbSNP | Ensembl ]

Sequence information Variant position:

301 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

391 The length of the canonical sequence.
Location on the sequence:

LASPTPADIGSSVPGPQSYP I VTGRDLASTTLPGYPPHVPP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LASPTPADIGSSVPGPQSYPIVTGRDLASTTLPGYPPHVPP

Mouse                         LTSPTPADIGSSVPGPQSYPIVTGRDLASTTLPGYPPHVPP

Xenopus laevis                LTSPSSADIGGTVPGPQSYPLVTGRDLASTTLPGYPPHVPP

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 391	Paired box protein Pax-5
Alternative sequence	261 – 391	TTEYSAMASLAGGLDDMKANLASPTPADIGSSVPGPQSYPIVTGRDLASTTLPGYPPHVPPAGQGSYSAPTLTGMVPGSEFSGSPYSHPQYSSYNDSWRFPNPGLLGSPYYYSAAARGAAPPAAATAYDRH -> AVTWRARPSPGTLHTSPPLDRAATQHRR. In isoform 5.
Alternative sequence	261 – 315	TTEYSAMASLAGGLDDMKANLASPTPADIGSSVPGPQSYPIVTGRDLASTTLPGY -> APPIIIALPPEE. In isoform 4.
Alternative sequence	261 – 307	TTEYSAMASLAGGLDDMKANLASPTPADIGSSVPGPQSYPIVTGRDL -> WCPVLMRQYLVQPQAVLFQAVTWRARPSPGTLHTSPPLDRAATQHRR. In isoform 11.
Alternative sequence	286 – 315	PADIGSSVPGPQSYPIVTGRDLASTTLPGY -> RGCLAPPIIIALPPEE. In isoform 3.

Literature citations
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.
Shah S.; Schrader K.A.; Waanders E.; Timms A.E.; Vijai J.; Miething C.; Wechsler J.; Yang J.; Hayes J.; Klein R.J.; Zhang J.; Wei L.; Wu G.; Rusch M.; Nagahawatte P.; Ma J.; Chen S.C.; Song G.; Cheng J.; Meyers P.; Bhojwani D.; Jhanwar S.; Maslak P.; Fleisher M.; Littman J.; Offit L.; Rau-Murthy R.; Fleischut M.H.; Corines M.; Murali R.; Gao X.; Manschreck C.; Kitzing T.; Murty V.V.; Raimondi S.C.; Kuiper R.P.; Simons A.; Schiffman J.D.; Onel K.; Plon S.E.; Wheeler D.A.; Ritter D.; Ziegler D.S.; Tucker K.; Sutton R.; Chenevix-Trench G.; Li J.; Huntsman D.G.; Hansford S.; Senz J.; Walsh T.; Lee M.; Hahn C.N.; Roberts K.G.; King M.C.; Lo S.M.; Levine R.L.; Viale A.; Socci N.D.; Nathanson K.L.; Scott H.S.; Daly M.; Lipkin S.M.; Lowe S.W.; Downing J.R.; Altshuler D.; Sandlund J.T.; Horwitz M.S.; Mullighan C.G.; Offit K.;
Nat. Genet. 45:1226-1231(2013)
Cited for: VARIANT ALL3 SER-183; VARIANTS ARG-24; GLY-26; GLN-34; VAL-53; GLY-59; ASN-66; ARG-75; ARG-80; THR-139; ILE-151; VAL-183; LEU-213; THR-301 AND VAL-338; CHARACTERIZATION OF VARIANT ALL3 SER-183;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.